latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/danaher-closes-21-4b-acquisition-of-ge-s-biopharma-business-57846401 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Danaher closes $21.4B acquisition of GE's biopharma business

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks

Gauging Supply Chain Risk In Volatile Times


Danaher closes $21.4B acquisition of GE's biopharma business

Danaher Corp. has completed its $21.4 billion acquisition of General Electric Co.'s biopharma business.

The total consideration included about $21 billion in cash as well as Danaher's assumption of certain pension liabilities. After taking into account deal taxes, deal fees and factored receivable balances, GE's net proceeds from the transaction were about $20 billion, according to a March 31 news release.

GE's biopharma business, which was part of the GE Life Sciences division, provides equipment and software used in biopharmaceutical research. As part of the Washington, D.C.-based maker of medical, industrial and commercial products and services, the business will be called Cytiva and will be a stand-alone company within Danaher's life sciences segment.

The acquisition was previously cleared by the U.S. Federal Trade Commission, the European Commission and antitrust authorities in Brazil, China, Israel, Japan, South Korea and Russia after Danaher divested certain assets to ease antitrust concerns regarding the deal.